Abstract
In modern times, heart failure has increasingly become a major public health issue, with a prevalence of approximately 5.1 million in North America [1]. Furthermore, one in 7 Americans are age 65 or greater, with this proportion set to rise to one in 5 by 2050 [2]. Given the age-dependent increase in incidence and prevalence of heart failure, the proportion of heart failure will only continue to increase; already, it is one of the main causes of death and hospitalization in this age group. Combined with demographic improvements in life expectancies and recent improvements in the treatment of heart-failure, the proportion of patients that develop advanced heart failure has also increased substantially. The majority of patients with so-called “end-stage” heart failure are characterized by advanced structural heart disease and profound symptoms of heart failure at rest or upon minimal exertion despite maximal guideline-directed medical treatment, and typically fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification (see Table 1.2 for a full explanation of heart failure classifications). There are varying etiologies of such severe heart failure, which can broadly be divided into ischemic and non-ischemic; these may include unstable arrhythmias, idiopathic cardiomyopathies and many others. Regardless of the etiology, the subgroup of stage D heart failure demonstrates a particularly high 5-year mortality rate of 80% [1], and thus requires special therapeutic interventions. This chapter will assume background knowledge in the principles of heart failure and its early management, and will cover current medical and device strategies for the management of end-stage heart failure, with acknowledgement to the options of mechanical circulatory support and cardiac transplantation which will be covered in detail in upcoming chapters.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.
Washington, DC: US Department of Health and Human Services. 2014.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282–93. [Epub ahead of print]
Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet. 2000;355(9215):1575–81.
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772–6.
Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.
Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70(2):234–9.
Parker JO. The effects of oral ibopamine in patients with mild heart failure: a double blind placebo controlled comparison to furosemide: the Ibopamine study group. Int J Cardiol. 1993;40:221–7.
Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709–11.
Friedrich EB, Bohm M. Management of end stage heart failure Heart. Heart. 2007;93(5):626–31.
Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134(7):550–60.
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.
Pitt B, Zannad F, Remme WJ, et al. Randomized aldactone evaluation study investigators the effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
Carson P, Ziesche S, Johnson G, et al. Vasodilator-heart failure trial study group racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178–87.
Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a veterans administration cooperative study. N Engl J Med. 1986;314:1547–52.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.
The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988;259:539–44.
Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–94.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.
Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41(9):1573–82.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-second official adult heart transplantation report--2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1244–54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Hamilton, M., Kittleson, M., Kobashigawa, J. (2017). Medical and Device Options for Patients with End-Stage Heart Failure. In: Kobashigawa, J. (eds) Clinical Guide to Heart Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-43773-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-43773-6_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43771-2
Online ISBN: 978-3-319-43773-6
eBook Packages: MedicineMedicine (R0)